These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 25026375)
1. Modulation of Brahma expression by the mitogen-activated protein kinase/extracellular signal regulated kinase pathway is associated with changes in melanoma proliferation. Mehrotra A; Saladi SV; Trivedi AR; Aras S; Qi H; Jayanthy A; Setaluri V; de la Serna IL Arch Biochem Biophys; 2014 Dec; 563():125-35. PubMed ID: 25026375 [TBL] [Abstract][Full Text] [Related]
2. Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma. Keenen B; Qi H; Saladi SV; Yeung M; de la Serna IL Oncogene; 2010 Jan; 29(1):81-92. PubMed ID: 19784067 [TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation in human melanoma: past and future. Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943 [TBL] [Abstract][Full Text] [Related]
5. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506 [TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of Drosophila Brahma on CDK-phosphorylation sites is important for cell cycle regulation and differentiation. Roesley SNA; La Marca JE; Deans AJ; Mckenzie L; Suryadinata R; Burke P; Portela M; Wang H; Bernard O; Sarcevic B; Richardson HE Cell Cycle; 2018; 17(13):1559-1578. PubMed ID: 29963966 [TBL] [Abstract][Full Text] [Related]
7. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656 [TBL] [Abstract][Full Text] [Related]
8. SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells. Vachtenheim J; Ondrusová L; Borovanský J Biochem Biophys Res Commun; 2010 Feb; 392(3):454-9. PubMed ID: 20083088 [TBL] [Abstract][Full Text] [Related]
9. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Hoffman GR; Rahal R; Buxton F; Xiang K; McAllister G; Frias E; Bagdasarian L; Huber J; Lindeman A; Chen D; Romero R; Ramadan N; Phadke T; Haas K; Jaskelioff M; Wilson BG; Meyer MJ; Saenz-Vash V; Zhai H; Myer VE; Porter JA; Keen N; McLaughlin ME; Mickanin C; Roberts CW; Stegmeier F; Jagani Z Proc Natl Acad Sci U S A; 2014 Feb; 111(8):3128-33. PubMed ID: 24520176 [TBL] [Abstract][Full Text] [Related]
10. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Reisman DN; Strobeck MW; Betz BL; Sciariotta J; Funkhouser W; Murchardt C; Yaniv M; Sherman LS; Knudsen ES; Weissman BE Oncogene; 2002 Feb; 21(8):1196-207. PubMed ID: 11850839 [TBL] [Abstract][Full Text] [Related]
11. MITF-independent pro-survival role of BRG1-containing SWI/SNF complex in melanoma cells. Ondrušová L; Vachtenheim J; Réda J; Záková P; Benková K PLoS One; 2013; 8(1):e54110. PubMed ID: 23349796 [TBL] [Abstract][Full Text] [Related]
13. E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis. Montagnani V; Maresca L; Apollo A; Pepe S; Carr RM; Fernandez-Zapico ME; Stecca B J Biol Chem; 2020 Nov; 295(47):16058-16071. PubMed ID: 32938713 [TBL] [Abstract][Full Text] [Related]
14. Modulation of extracellular matrix/adhesion molecule expression by BRG1 is associated with increased melanoma invasiveness. Saladi SV; Keenen B; Marathe HG; Qi H; Chin KV; de la Serna IL Mol Cancer; 2010 Oct; 9():280. PubMed ID: 20969766 [TBL] [Abstract][Full Text] [Related]
15. BRG1 promotes survival of UV-irradiated melanoma cells by cooperating with MITF to activate the melanoma inhibitor of apoptosis gene. Saladi SV; Wong PG; Trivedi AR; Marathe HG; Keenen B; Aras S; Liew ZQ; Setaluri V; de la Serna IL Pigment Cell Melanoma Res; 2013 May; 26(3):377-91. PubMed ID: 23480510 [TBL] [Abstract][Full Text] [Related]
16. Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence. de Keizer PL; Packer LM; Szypowska AA; Riedl-Polderman PE; van den Broek NJ; de Bruin A; Dansen TB; Marais R; Brenkman AB; Burgering BM Cancer Res; 2010 Nov; 70(21):8526-36. PubMed ID: 20959475 [TBL] [Abstract][Full Text] [Related]
17. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758 [TBL] [Abstract][Full Text] [Related]
19. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239 [TBL] [Abstract][Full Text] [Related]